Indication-specific Drug Pricing - Simple in Theory, Complex in Reality
- PMID: 29763404
Item in Clipboard
Indication-specific Drug Pricing - Simple in Theory, Complex in Reality
Manag Care.
2018 May.
Abstract
Varying drug prices by indication could be an important value-based strategy in oncology, where multiple indications are becoming the rule. But will administrative costs offset any benefit? And legal and regulatory obstacles could get in the way.
Keywords: Drug Costs; Health Care Costs; Pharmaceutical Economics; Pharmacoeconomics.
Similar articles
-
Cost of Cancer Drugs: Something Has To Give.Manag Care. 2018 May;27(5):18-22. Manag Care. 2018. PMID: 29763403
-
Pricing in the Market for Anticancer Drugs.J Econ Perspect. 2015;29(1):139-62. doi: 10.1257/jep.29.1.139. J Econ Perspect. 2015. PMID: 28441702 No abstract available.
-
Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?Pharmacoeconomics. 2018 Dec;36(12):1407-1420. doi: 10.1007/s40273-018-0716-4. Pharmacoeconomics. 2018. PMID: 30198061
-
The high price of anticancer drugs: origins, implications, barriers, solutions.Nat Rev Clin Oncol. 2017 Jun;14(6):381-390. doi: 10.1038/nrclinonc.2017.31. Epub 2017 Mar 14. Nat Rev Clin Oncol. 2017. PMID: 28290490 Review.
-
The economics of prescription drug prices, government intervention, and the importation of drugs from Canada.Nurs Econ. 2005 Nov-Dec;23(6):307-11, 279. Nurs Econ. 2005. PMID: 16459902 Review.